Amarin’s REDUCE-IT Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results

Biotech Investing

Amarin (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today commented that following this week’s European Society of Cardiology (ESC) Congress in Munich, Germany, Amarin’s landmark cardiovascular outcomes study, REDUCE-IT, is now likely to be the next large cardiovascular outcomes study to report results. As quoted in the …

Amarin (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today commented that following this week’s European Society of Cardiology (ESC) Congress in Munich, Germany, Amarin’s landmark cardiovascular outcomes study, REDUCE-IT, is now likely to be the next large cardiovascular outcomes study to report results.

As quoted in the press release:

As previously guided, top-line results from the REDUCE-IT study are expected to be reported before the end of September 2018. REDUCE-IT is evaluating the effect of Vascepa® (icosapent ethyl), administered at four (4) grams per day, as an add-on to statin therapy, on major adverse cardiovascular events (MACE) as compared to statin treated patients plus placebo.  REDUCE-IT is the first cardiovascular outcomes study to be conducted in patients who despite low density lipoprotein cholesterol (LDL-C) control have risk factors for cardiovascular disease, including elevated triglyceride levels.

Deaths from cardiovascular disease are increasingly creating a worsening public health burden along with considerable pain, suffering and lost productivity. In the United States, heart disease is responsible for more than 800,000 deaths per year which is more deaths than from all types of cancer combined.

Click here to read the full press release.

The Conversation (0)
×